The use of a deep learning model in the histopathological diagnosis of actinic keratosis: A case control accuracy study

Competing Interest Statement

J. Balkenhol: none; L. Schmitz: Honoraria from Almirall, Beiersdorf, Biofrontera, Galderma, Mylan, Sanofi; T. Dirschka: Lecture fees from Almirall, Biofrontera, Galderma, Leo, Meda, Riemser, Janssen; member of advisory boards for Almirall, Biofrontera, infectopharm, Leo, Meda, Novartis, Riemser, Janssen; unrestricted grants from Meda and Galderma; Tim Schnauder: none; Johannes Langhorst: none; Maximilian Schmidt: German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF); Daniel Otero Baguer: German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF); Jean Le Clerc Arrastia: German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF); G. Gilbert: none

Funding Statement

M Schmidt, D. Otero Baguer, and J. Le Clerc Arrastia acknowledge the financial support by the German Federal Ministry for Economic Affairs and Climate Action (BMWK) and the European Social Fund (ESF) within the EXIST Transfer of Research project aisencia'.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was performed in accordance with the approval of the ethics committee of the University Witten-Herdecke (Proposal-No. 105/2022). The study retrospectively analyzes patient samples that have been gained in the clinical routine and have been processed in an anonymized way.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes